0.08
+0.0111(+15.04%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.09 |
| Day High | 0.11 |
| Day Low | 0.08 |
| 52-Week High | 4.95 |
| 52-Week Low | 0.06 |
| Volume | 461.19M |
| Average Volume | 23.46M |
| Market Cap | 1.36M |
| PE | -0.03 |
| EPS | -2.91 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 1.78 |
| Change | 0.01 |
If you invested $1000 in GlucoTrack, Inc. (GCTK) 10 years ago, it would be worth $1.14 as of January 19, 2025 at a share price of $0.085. Whereas If you bought $1000 worth of GlucoTrack, Inc. (GCTK) shares 5 years ago, it would be worth $3.53 as of January 19, 2025 at a share price of $0.085.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
GlobeNewswire Inc.
Jan 15, 2025 1:01 PM GMT
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”
Glucotrack to Present at TechBio Showcase™ 2025
GlobeNewswire Inc.
Jan 07, 2025 9:05 PM GMT
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetesRUTHERFORD, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical techn
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
GlobeNewswire Inc.
Dec 03, 2024 1:30 PM GMT
Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks Rutherford, NJ, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or th